



The International Pharmaceutical Excipients Council

Incorporation of Pharmaceutical Excipients into Product Development using Quality-by-Design (QbD)

Version 2
2025

This document represents voluntary guidance for the excipient industry and the contents should not be interpreted as regulatory requirements. Alternatives to the approaches in this Guide may be used to achieve an equivalent level of assurance for excipient quality.

This guide was created to help companies understand current expectations on this topic and is not intended for use by third party certification bodies to conduct audits or to certify compliance with this guide.


The content of this guide cannot be reproduced without the written authorisation of the IPEC Federation Management Body.

FOREWORD

The International Pharmaceutical Excipients Council (IPEC) is an international industry association formed by excipient manufacturers, distributors and end-users. At the time of writing, there are regional pharmaceutical excipient industry associations located in the Americas, Europe, Japan, China, and India. IPEC's objective is to contribute to international excipient standards development and harmonization, provide useful information for new excipient development and introduction, and offer best practice and guidance concerning excipient development.

IPEC has three major stakeholder groups;

1. Excipient manufacturers and distributors, defined as suppliers in this document.
2. Medicinal (drug) product manufacturers, defined as *excipient users* in this document, and
3. Public health and regulatory authorities



This Guide is intended to be voluntary, to indicate best practice, and to be globally applicable. However, it should be recognized that the laws and regulations applying to excipients will vary from region to region, and country to country. In addition, the rules and regulations are continually evolving. It is the responsibility of the reader to review the most current version of any applicable

regulatory requirements. Versions referenced in this guide were based on versions available at the time the guide was published.

In this guide, pharmaceutical excipient(s) will be referred to as excipient(s). This guide may be applied to veterinary medicines, as appropriate and include reference to specific veterinary guidances and regulations.

Throughout the guide, justification implies that a decision is made based on sound scientific, quality and/or regulatory considerations.

This Guide offers current best practice and voluntary guidance on the incorporation of excipients and excipient variability into Quality-by-Design (QbD) pharmaceutical finished product development programs. It is important that the reader confirms this is the latest version of the guide as found on www.ipec-federation.org or regional IPEC websites.

***NOTE:** Refer to the “International Pharmaceutical Excipient Council Glossary: General Glossary of Terms and Acronyms” for definitions [1]. The first use of a term found in the glossary will be in **BOLD**.*

Table of Contents (TOC)

FOREWORD	1
ACKNOWLEDGEMENTS	5
1 INTRODUCTION	6
1.1 Purpose	6
1.2 Scope	6
1.3 Principles Adopted	7
2 BACKGROUND AND GENERAL GUIDANCE	8
2.1 An Introduction to Drug and Drug Product Development	8
2.2 Quality-by-Design	10
2.3 Excipients	15
2.4 Pharmaceutical Products	19
3 INCORPORATION OF EXCIPIENTS INTO THE FORMULATION	20
3.1 Excipient Selection	20
3.2 Formulation and Process Design and Development	21
3.3 Risk Assessment	21
3.4 Design of Experiments	23
3.5 Design Space and Control Strategy	23
4 EXCIPIENTS IN QUALITY-BY-DESIGN	24
4.1 Introduction	24
4.2 Excipient Impact Categorization	30
4.3 Critical Material Attributes	30
4.4 Analysis of the Design of Experiments (DoE)	33
4.5 Scale-up	34
5 LIFECYCLE MANAGEMENT	35
5.1 Continued Monitoring	35
5.2 Multivariate Analysis (MVA)	35
5.3 Continued Product Verification	36
5.4 Detection of Product/Excipient Drift and Out-of-Trend Results	36
5.5 Excipient-related Special Cause Variation in Production	36

6 REFERENCES	39
ANNEX A Pharmaceutical Development Process.....	42
ANNEX B Provision of Samples to Support QbD Studies.....	44
ANNEX C Kano Analysis	51

Table of Tables

Table 1: The criticality of Lactose Particle Size Distribution in different dose forms	31
---	-----------

Table of Figures

Figure 1 Medicinal Drug Development Process	8
Figure 2 ICH Quality Roadmap [21].....	11
Figure 3 Relationship between Edge of Failure/Proven Acceptable Range, Design Space, and Normal Operating Range	13
Figure 4 Reducing Product Variability [21].....	13
Figure 5 Simple Process Capability Model.....	29

ACKNOWLEDGEMENTS

This guide was developed by representatives of the associations which constitute the IPEC Federation (IPEC). The IPEC Federation greatly appreciates the many hours devoted by the core team of individuals and other contributors listed below, to make this guide available to IPEC members and the broader excipient community. Equally, IPEC extends its thanks to the employers of those same contributors who provided the necessary time and resources, without which, this guide would not be possible.

List of Contributors from IPEC-Americas

Brian Carlin, Ph.D. (Chair), Carlin Pharma Consulting LLC
David Schoneker (Vice-Chair), Black Diamond Regulatory Consulting, LLC
R. Christian Moreton, Ph.D, FinnBrit Consulting
Katherine Ulman, KLU Consulting, LLC
Joseph Zeleznik, IMCD US

List of Contributors from IPEC China

Panpan Hu, IFF China
Cissy Wang, Ashland
Shine Gao, Ingredion